Skip to Content

Safe to use Belantamab Mafodotin for transplant-ineligible patients with newly diagnosed multiple myeloma

Current treatment regime for transplant-ineligible patients with newly diagnosed multiple myeloma is lenalidomide plus dexamethasone (Rd). Addition of Belantamab Mafodotinn (belamaf) has shown to lead to higher responses. In this MEDtalk Dr. Evangelos Terpos presents an open-label single center study investigating the safety profile of belamaf in three different treatment doses ranging between 1,4-2,5 mg/kg. Results suggest no new safety signals in the belamaf-Rd combination.

Evangelos Terpos

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top